關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。

Patent Application by TJP Labs Inc. Signals Breakthrough in Nicotine Pouch Technology

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 445 加入收藏 :

TORONTO, April 11, 2024 /PRNewswire/ -- TJP Labs, spearheading innovation in oral pouch manufacturing, is proud to announce a ground-breaking patent filing for a novel nicotine particulate. This innovative particulate, which dramatically increases the speed of nicotine release, is poised to revolutionize harm reduction and substantially improve the consumer experience.

TJP Labs Logo www.tjplabs.com
TJP Labs Logo www.tjplabs.com

Distinct features of this novel technology include:

  • Superior Nicotine Release: Far outpacing Polacrilex for a more effective delivery.
  • Versatile Particulate Size Customization: From ultra-fine to several hundred microns for precise product design.
  • Precision-Targeted Binding:  Improves nicotine release rate, which enhances effectiveness.
  • Broad Spectrum of Adaptable Core Materials: Expands product versatility and application possibilities.
  • Efficient Raw Material Use: Nicotine loading several orders of magnitude over Polacrilex, enhancing efficiency.
  • Eco-Friendly and Versatile Composition: Optimized for organic and inorganic forms, including biodegradable resins, enabling diverse, innovative applications.
  • Streamlined Manufacturing: Swift, optimized manufacturing process that accelerates product development.
  • Seamless Integration: Designed for easy incorporation into nicotine pouch formats and related products.

With the meteoric rise of the nicotine pouch market as a safer alternative, TJP Labs is well-positioned to capitalize on the industry's race for innovation, meeting and surpassing the rising demand with superior, cutting-edge products. The newly developed particulate marks a critical breakthrough in Nicotine Replacement Therapies.

"This landmark initiative powerfully showcases TJP Labs' commitment to redefining nicotine consumption through innovation," said David Richmond-Peck, Chief Relationship Officer of TJP Labs. "With other innovations in our pipeline, safeguarding our intellectual property remains integral to our strategy, matching our innovative efforts with consumers' evolving preferences," he added.

TJP Labs anticipates the availability of initial evaluation data for these particulates by late the second quarter of 2024. TJP Labs remains dedicated to relentlessly pursuing advancements that enhance the lives of individuals seeking to responsibly manage their consumption of nicotine.

About TJP Labs Inc. 

TJP Labs Inc., a wholly owned subsidiary of KIK ASS Products Inc., is North America's leading full-service contract manufacturer of premier next-generation products focusing on modern oral nicotine. It provides contract manufacturing services to an affiliated company that focuses on energy products, including caffeine. 

Our products are manufactured and packaged in our DEL, cGMP compliant, ISO 9001:2015 certified state-of-the-art facilities.

For more information about TJP Labs and the innovative nicotine particulate, please contact innovation@tjplabs.com

 

 

以上新聞投稿內容由 PR Newswire 美通社 全權自負責任,若有涉及任何違反法令、違反本網站會員條款、有侵害第三人權益之虞,將一概由 PR Newswire 美通社 承擔法律及損害賠償之責任,與台灣產經新聞網無關。

Tags :
首 頁 我的收藏 搜 尋 新聞發佈